Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink(University Medical Center Groningen), David C. Wheeler(University College London), Fan Fan Hou(Southern Medical University), John J.V. McMurray(University of Glasgow), Glenn M. Chertow(Stanford Health Care), C. David Sjöström(University Medical Center Groningen), Johannes F.E. Mann(Katholische Stiftungshochschule München), Ricardo Correa‐Rotter(University Medical Center Groningen), Bergur V. Stefánsson(University Medical Center Groningen), Peter Rossing(Steno Diabetes Centers), Anna-Maria Langkilde(University Medical Center Groningen), Tom Greene(University Medical Center Groningen), Roberto D. Toto(University Medical Center Groningen), Magnus Lindberg(University of Gävle)
Cited by 5,153
Related Papers
A New Equation to Estimate Glomerular Filtration Rate
|Annals of Internal Medicine|2009|25.7k
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k